deucravacitinib,baricitinib,tofacitinib,upadacitinib
bms,eli lilly,pfizer,abbvie
['upadacitinib']
 great talk and handy slide please note that upadacitinib is jak1 preferential inhibitor - *not* strictly jak1 selective there is no jak1 homodimer #acr22
Rheumatologist | Physician |  Portsmouth Hospitals University NHS Trust UK | Views my own | Re-tweets do not mean endorsement | Mainly clinical news/updates